Physician profile
Peter J Goadsby
NPI 1164606943
$708,909.29
in general payments reported to CMS, 2019-2025
18 companies · $94K in 2025
The $94K reported for 2025 was more than what 98% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $93K · 2020: $52K · 2021: $92K · 2022: $242K · 2023: $71K · 2024: $64K · 2025: $94K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $179K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Travel and Lodging: $14K · Food and Beverage: $1,569.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $178,867.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $34,932.98 |
| Travel and Lodging | $13,824.49 |
| Food and Beverage | $1,569.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| H. Lundbeck A S | $187,896.37 | 2021-2023 | Vyepti |
| Abbvie INC. | $135,984.05 | 2021-2025 | |
| Pfizer INC. | $126,784.73 | 2022-2025 | |
| Eli Lilly and Company | $77,320.06 | 2019-2022 | |
| Amgen INC. | $62,269.15 | 2019-2023 | Aimovig |
| Lilly USA, LLC | $45,260.34 | 2019-2022 | |
| Allergan, INC. | $29,304.63 | 2019-2021 | |
| Lundbeck LLC | $15,441.43 | 2021-2023 | Vyepti |
| Biohaven Pharmaceuticals, INC. | $13,945.66 | 2021 | |
| Bausch Health US, LLC | $6,250.00 | 2024-2025 | |
| Biodelivery Sciences International, INC. | $3,000.00 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $1,350.00 | 2022 | |
| Biogen, INC. | $1,250.00 | 2021 | |
| Scilex Pharmaceuticals INC. | $1,200.00 | 2023 | Elyxyb |
| Dr.Reddy'S Laboratories,INC. | $990.00 | 2020-2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cipla USA INC. | $500.00 | 2019 | |
| Hyperfine Operations, INC. | $122.95 | 2025 | Swoop |
| Depuy Synthes Sales INC. | $39.92 | 2025 | Cerepak Uniform |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Goadsby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.